These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 16479242

  • 1. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer.
    Kumar R, Zhuang H, Schnall M, Conant E, Damia S, Weinstein S, Chandra P, Czerniecki B, Alavi A.
    Nucl Med Commun; 2006 Mar; 27(3):231-6. PubMed ID: 16479242
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy.
    Fehr MK, Hornung R, Varga Z, Burger D, Hess T, Haller U, Fink D, von Schulthess GK, Steinert HC.
    Breast J; 2004 Mar; 10(2):89-93. PubMed ID: 15009033
    [Abstract] [Full Text] [Related]

  • 7. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
    Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, Spano G, Luini A, Intra M, Veronesi P, Berrettini A, Paganelli G.
    Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
    Pritchard KI, Julian JA, Holloway CM, McCready D, Gulenchyn KY, George R, Hodgson N, Lovrics P, Perera F, Elavathil L, O'Malley FP, Down N, Bodurtha A, Shelley W, Levine MN.
    J Clin Oncol; 2012 Apr 20; 30(12):1274-9. PubMed ID: 22393089
    [Abstract] [Full Text] [Related]

  • 10. Factors affecting the accuracy of 18F-FDG PET/CT in evaluating axillary metastases in invasive breast cancer.
    Kutluturk K, Simsek A, Comak A, Gonultas F, Unal B, Kekilli E.
    Niger J Clin Pract; 2019 Jan 20; 22(1):63-68. PubMed ID: 30666022
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R, Micheli A, Asero S, Ferraris C, Gennaro M, Bombardieri E, Cascinelli N.
    J Natl Cancer Inst; 2001 Apr 18; 93(8):630-5. PubMed ID: 11309439
    [Abstract] [Full Text] [Related]

  • 13. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience.
    Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, Song I, Kim Y, Lee C.
    World J Surg; 2009 May 18; 33(5):943-9. PubMed ID: 19259728
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer.
    Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S.
    Ann Surg Oncol; 2003 Jul 18; 10(6):622-7. PubMed ID: 12839846
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT.
    Futamura M, Asano T, Kobayashi K, Morimitsu K, Nawa M, Kanematsu M, Morikawa A, Mori R, Yoshida K.
    World J Surg Oncol; 2015 Feb 14; 13():49. PubMed ID: 25885028
    [Abstract] [Full Text] [Related]

  • 17. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
    van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D, Meijer S, Lammertsma AA, Teule GJ.
    Ann Surg; 2002 Nov 14; 236(5):619-24. PubMed ID: 12409668
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase.
    Goyal A, Newcombe RG, Chhabra A, Mansel RE, ALMANAC Trialists Group.
    Breast Cancer Res Treat; 2006 Sep 14; 99(2):203-8. PubMed ID: 16541308
    [Abstract] [Full Text] [Related]

  • 20. Reliability of predicting low-burden (≤ 2) positive axillary lymph nodes indicating sentinel lymph node biopsy in primary operable breast cancer - a retrospective comparative study with PET/CT and breast MRI.
    Sae-Lim C, Wu WP, Chang MC, Lai HW, Chen ST, Chou CT, Liao CY, Huang HI, Chen ST, Chen DR, Hung CL.
    World J Surg Oncol; 2024 Jan 06; 22(1):12. PubMed ID: 38183069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.